Deals
What Would Help Takeda Afford Shire? Subtracting Its ADHD Unit
This article is for subscribers only.
Takeda Pharmaceutical Co.’s potential offer for Shire Plc doesn’t look like quite as much of a stretch if you subtract a key piece.
Takeda cited Shire’s neuroscience division among the assets it would gain with the possible purchase. Shire said in August that it was considering a spinoff of the unit, which makes treatments for hyperactivity and attention-deficit disorders.